Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19
Executive Summary
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.
You may also be interested in...
23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.